Treatment of etoposide combined with 15-deoxy‑∆12,14‑prostaglandin J2 exerted synergistic antitumor effects against renal cell carcinoma via peroxisome proliferator‑activated receptor‑γ‑independent pathways

  • Authors:
    • Yasuhiro Yamamoto
    • Hiromi Koma
    • Hiroki Hiramatsu
    • Misa Abe
    • Kazunori Murakami
    • Asako Ohya
    • Tatsurou Yagami
  • View Affiliations

  • Published online on: December 24, 2013     https://doi.org/10.3892/mco.2013.234
  • Pages: 292-296
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Renal cell carcinoma (RCC) is characterized by diverse clinical manifestations, few early warning signs and a resistance to radiotherapy and chemotherapy. Although several clinical trials have investigated potential effective therapeutic strategies for RCC, the chemoresistance of RCC has not yet been overcome. An endogenous ligand for the peroxisome proliferator‑activated receptor‑γ (PPARγ), 15‑deoxy‑Δ12,14‑prostaglandin J2 (15d‑PGJ2), was shown to induce apoptosis in RCC. The aim of the present study was to investigate the synergistic effects of carcinostatics on the antitumor activity of 15d‑PGJ2 in the Caki‑2 human RCC cell line with the MTT assay. Our results demonstrated that the topoisomerase‑II inhibitor etoposide (VP‑16) exhibited cytotoxic effects synergistically with 15d‑PGJ2. Furthermore, the presence of the PPARγ antagonist GW9662 did not protect Caki‑2 cells against 15d‑PGJ2‑induced cytotoxicity. Additionally, it was observed that the combined treatment of VP‑16 and 15d‑PGJ2 activated caspase‑3 more efficiently compared to each treatment alone. Therefore, the combined treatment with 15d‑PGJ2 and VP‑16 exhibited synergistic antitumor activity independently of PPARγ.
View Figures
View References

Related Articles

Journal Cover

March 2014
Volume 2 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yamamoto, Y., Koma, H., Hiramatsu, H., Abe, M., Murakami, K., Ohya, A., & Yagami, T. (2014). Treatment of etoposide combined with 15-deoxy‑∆12,14‑prostaglandin J2 exerted synergistic antitumor effects against renal cell carcinoma via peroxisome proliferator‑activated receptor‑γ‑independent pathways. Molecular and Clinical Oncology, 2, 292-296. https://doi.org/10.3892/mco.2013.234
MLA
Yamamoto, Y., Koma, H., Hiramatsu, H., Abe, M., Murakami, K., Ohya, A., Yagami, T."Treatment of etoposide combined with 15-deoxy‑∆12,14‑prostaglandin J2 exerted synergistic antitumor effects against renal cell carcinoma via peroxisome proliferator‑activated receptor‑γ‑independent pathways". Molecular and Clinical Oncology 2.2 (2014): 292-296.
Chicago
Yamamoto, Y., Koma, H., Hiramatsu, H., Abe, M., Murakami, K., Ohya, A., Yagami, T."Treatment of etoposide combined with 15-deoxy‑∆12,14‑prostaglandin J2 exerted synergistic antitumor effects against renal cell carcinoma via peroxisome proliferator‑activated receptor‑γ‑independent pathways". Molecular and Clinical Oncology 2, no. 2 (2014): 292-296. https://doi.org/10.3892/mco.2013.234